Packaging insulin into a pill-friendly form for diabetes treatment

December 18, 2013, American Chemical Society
Packaging insulin into a pill-friendly form for diabetes treatment

Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary—and weary—patients to take their medicine when they should.

Sanyog Jain and colleagues explain that patients with diabetes sometimes skip doses or stop taking their because the injections can be painful. But doing so puts their health in danger. An estimated 347 million people globally (about 26 million in the U.S.) are living with diabetes. In the U.S., more than a quarter of these patients are taking some kind of . For years, researchers have sought a way to transform delivery of this therapy from a shot to a pill, but it has been a challenge. The body's digestive enzymes that are so good at breaking down food also break down insulin before it can get to work. In addition, insulin doesn't get easily absorbed through the gut into the bloodstream. To overcome these hurdles, Jain's team combined two approaches to shield insulin from the and then get it into the blood.

They packaged insulin in tiny sacs made of lipids, or fats, called liposomes, which are already used in some treatments. Then, they wrapped the liposomes in layers of protective molecules called polyelectrolytes. To help these "layersomes" get absorbed into the bloodstream, they attached folic acid, a kind of vitamin B that has been shown to help transport liposomes across the intestinal wall into the blood. In rats, the delivery system lowered almost as much as injected insulin, though the effects of the layersomes lasted longer than that of injected insulin.

Explore further: Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes

More information: "Improved Stability and Antidiabetic Potential of Insulin Containing Folic Acid Functionalized Polymer Stabilized Multilayered Liposomes Following Oral Administration" Biomacromolecules, Article ASAP. DOI: 10.1021/bm401580k

The present study reports the folic acid (FA) functionalized insulin loaded stable liposomes with improved bioavailability following oral administration. Liposomes were stabilized by alternating coating of negatively charged poly(acrylic acid) (PAA) and positively charged poly(allyl amine) hydrochloride (PAH) over liposomes. Furthermore, folic acid was appended as targeting ligand by synthesizing folic acid–poly(allyl amine) hydrochloride conjugate. The insulin entrapped within the freeze-dried formulation was found stable both chemically as well as conformationally and developed formulation exhibited excellent stability in simulated biological fluids. Caco-2 cell and ex vivo intestinal uptake studies revealed higher uptake of folic acid functionalized layersomes in comparison with their plain counterparts. In vivo pharmacodynamic and pharmacokinetic studies further revealed almost double hypoglycemia and approximately 20% relative bioavailability in comparison with subcutaneously administered standard insulin solution. Overall the proposed strategy is expected to contribute significantly in the field of designing ligand-anchored, polyelectrolyte-based stable systems in drug delivery.

Related Stories

Ultrasound, nanoparticles may help diabetics avoid the needle

November 21, 2013

A new nanotechnology-based technique for regulating blood sugar in diabetics may give patients the ability to release insulin painlessly using a small ultrasound device, allowing them to go days between injections – rather ...

Recommended for you

Synthetic carbohydrate wards off pneumococcal infections

March 22, 2018

More effective vaccines against certain forms of pneumonia and meningitis could soon be available. A team of scientists at the Max Planck Institute of Colloids and Interfaces in Potsdam has identified a synthetic carbohydrate ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jan 13, 2014
Beginning in 2005 with Dr. Jill Crandall's human clinical trial using Transmax resveratrol, the form of this natural compound used in clinical trials and available as a dietary supplement at the Albert Einstein Med. College, in which this type of resveratrol was shown to lower blood glucose and insulin sensitivity in pre diabetics; through to the 2012 study at the JSS Pharmacy College using Biotivia Bioforte, and a large body of in-vitro evidence, amounting to over 5,000 published studies, solid scientific proof of resveratrol's potential benefits to Type 2 Diabetics and Obese persons is now well established. A recently published NIH study further confirmed the beneficial effect of Transmax Resveratrol on insulin sensitivity, glucose tolerance and LDL cholesterol.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.